Premenstrual dysphoric disorder. Other specified mood [affective] disorders
Conditions
Interventions
Intervention 1: Intervention group 1: Escitalopram manufactured in Abidi´s Pharmaceutical Company 10 milligram per day for three months. Intervention 2: Intervention group 2: Vitagnus tablets manufact
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Confirmed diagnosis of premenstrual dysphoric disorder To have regular menstrual periods Assignment the informed consent form of the study
Exclusion criteria
Exclusion criteria: Polycystic ovarian disease Irregular menstrual periods Psychiatric disorders: dementia, psychosis, mental retardation, opium or psychoactive drugs abuse and high mood Breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of premenstrual symptoms. Timepoint: At baseline (before initiation of the intervention) and at the end of the first, second and third months after the intervention. Method of measurement: Premenstrual Syndrome Diary (PMSD) questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| The presence of psychologic symptoms. Timepoint: Before intervention and at the end of the third month after intervention. Method of measurement: Revised 90- Scale Symptom Checklist (SCL-90-R). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSussan Moudi
Babol University of Medical Sciences
Outcome results
None listed